Endonovo Therapeutics Inc (OTCMKTS:ENDV) Should Run Further Near Term

On March 14, we published this piece looking at Endonovo Therapeutics Inc (OTCMKTS:ENDV). Our thesis was relatively simple – that the company was approaching a couple of key catalysts that looked set to inject some long awaited upside momentum into its (in our opinion) dramatically undervalued market capitalization. At the time, Endonovo shares could be had for a little over $0.03 a piece. The company just hit $.14 a share, and looks set to continue running near term. That's a close to 360% run in a couple of weeks.This really could be just the beginning, however.Why? Because this run has come without any of the above discussed catalysts actually hitting press – it's simple been a case of due diligence driven loading ahead of an anticipated Endonovo revaluation. As such, when we do see the news, it's going to draw speculative volume towards a stock that is fully loaded and poised to run.For those new to the company, it's a development stage biotech that's working to develop various technologies based on what's called electroceuticals. Basically, the company has taken some NASA technology that fires electromagnetic pulses into cells (it was originally tested as a way to treat astronauts in space to keep their cells healthy), adapted it a bit to make it more effective (the company's tech uses square waves as opposed to Sine or triangle waves, meaning it reaches peak intensity quicker) and packaged it into a handheld device that can be used to stimulate cell regeneration.The company is preclinical right now, and that's helped it remain under the radar, but as we noted last time, it's about to put out some data from a preclinical study of an iteration of the above described technology called Immunotronics in myocardial infarction (or heart attack, as it's more commonly known). People who have heart attacks often suffer complete heart failure subsequent to the attack. The idea behind the company's approach in this indication, is that electroceutical therapy using the immunotronics device in patients that have suffered heart attacks can reduce the risk of post MI heart failure through the strengthening and rejuvenation of the cells as part of a post MI treatment regiment. A study designed to support this hypothesis kicked off last year, and the initial target was for completion (and in turn, data release) from this study to occur during the first quarter of this year.Endonovo just reported the filing of a new patent application on the technology (it's already patented, but the company has a host of patents pending that serve to strengthen protection as applied to a widening range of therapy types), and alongside the release, dropped a bit of information relating to the study.Here's what the release said:

"The Company now anticipates initial results from its ongoing pre-clinical study in the second quarter of 2017."

For us, this is more important than the patent application announcement. When this data hits, and as described above, it's going to bring with it a degree of preclinical validation for the science, and should bridge to a clinical study near term. That's when the wider markets will start to take notice of the company, and when this one's going to start running.The second catalyst we noted last time was a pending uplisting. The company is going to have to raise its PPS if this uplisting is to take place, and there's the potential for a split to achieve this. That's a risk. With that said, there's a pretty large insider and institutional base, and the float is low, so there's a chance management (and certain investors) will try and boost PPS through alternative methods (buyback) with a view to avoiding an RS.That mitigates the split risk somewhat.Bottom line here is that this is a stock that is gaining steadily on no news, in anticipation of some upcoming data and an uplisting changing the game. That makes it well worth keeping an eye on in our view.We will be updating our subscribers as soon as we know more. For the latest updates on ENDV, sign up below!Disclosure: We have no position in ENDV and have not been compensated for this article.